Jury Still Out on Cardiovascular Safety of Testosterone

Despite a new meta-analysis claiming to show that testosterone replacement therapy for men with hypogonadism does not increase the risk of cardiovascular outcomes such as heart attack or stroke, experts say the jury has still not been tried. A more definitive answer for the cardiovascular safety of testosterone therapy will come from the AbbVie-sponsored TRAVERSE […]

Continue Reading